Condition

Abnormal Glucose Tolerance (3)

Cystic Fibrosis (1)

Diabetes (1)

Pancreatic Insufficiency (1)

Type 1 Diabetes (1)

Overall Status

Active, not recruiting (1)

Recruiting (1)

Unknown status (1)

Sign in for free

Phase

phase 2 (2)

n/a (1)

Sponsor

Eden Miller (1)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1)

University of Pennsylvania (1)

Collaborator

Children's Hospital of Philadelphia (1)

Juvenile Diabetes Research Foundation (1)

Pendulum Therapeutics (1)

Intervention

ctla4-ig (abatacept) (1)

dulaglutide 0.75mg/0.5ml inj pen (1)

placebo (1)

wbf-0031 (1)

Study Documents

Intervention Type

drug (2)

dietary supplement (1)

Funder Type

Industry (1)

NIH (1)

Other (1)

Study Type

Interventional (3)

abnormal glucose tolerance

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Cystic Fibrosis, Pancreatic Insufficiency, Abnormal Glucose Tolerance Trial in Philadelphia (Dulaglutide 0.75Mg/0.5Ml Inj Pen)

Recruiting

Cystic Fibrosis
+3 more

Dulaglutide 0.75Mg/0.5Ml Inj Pen

Philadelphia, Pennsylvania

University of Pennsylvania

Jan 11, 2023

Abnormal Glucose Tolerance, Type 1 Diabetes Trial in Canada, United States (CTLA4-Ig (Abatacept), Placebo)

Active, not recruiting

Abnormal Glucose Tolerance
Type 1 Diabetes

CTLA4-Ig (Abatacept)
Placebo

San Francisco, California
+16 more

Apr 13, 2022

Abnormal Glucose Tolerance Trial in Bend (WBF-0031)

Unknown status

Abnormal Glucose Tolerance

WBF-0031

Bend, Oregon

Diabetes and Obesity Care

Jul 27, 2020